Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan for VEGF Inhibitor-Associated Proteinuria
NCT07224776Phase 1Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sparsentan in proteinuria (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Change in urine to protein creatinine ratio at 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
sparsentan
03
Conditions
proteinuria
Beyond the preview
Go deeper on NCT07224776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07224776.